The PropThink Weekly Wrap-Up
- The FDA will decide on Lymphoseek’s approval in April, a major catalyst for Navidea (NAVB). Interest will again build in the some-what controversial name, and we expect the stock will climb significantly.
- On Wednesday, PropThink suggested using options to play Celsion’s ThermoDox data release. They’ve only gotten cheaper since. Was the sell-off a precursor to bad news, or just shareholders with cold feet?
- With the overhang of a financing removed at favorable terms, as well as full E.U. roll out and initiation of Esbriet sales in Canada, it looks like ITMN is positioned to move higher. And next year we’ll see pivotal data from the ASCEND trial, determinant of FDA approval.
- SGMO has made an impressive move in the early part of 2013, and the company is primed for a great year. Its HIV treatment could be a game-changer.
- Xenoport’s XP23829 is similar to Biogen Idec’s BG-12 in a good way. That, combined with a relaunch of Horizant and a late-stage spasticity candidate, make XNPT a quality asset.
- Pozen’s PA, while no blockbuster drug, will drive significant value for the company if it receives approval. Prospects are good, and the stock undervalued.
- We’ve followed Halozyme for some time. The stock got a lift early in the week from an analyst upgrade, and business developments (partnerships, product launches) continue to indicate upside from here.
- PropThink put PIP on the map (+17% in the session) last week when we wrote about ongoing litigation with SIGA Technologies. Of course, Premium Subscribers received advance notification and were able to take full advantage of the trade.
- Mr. Deryugin previewed Amgen’s 4th quarter expectations. Although the years of exponential growth are probably over, good times are still ahead for the “King of Biotech.”
- VPHM is well-positioned for gains, even though a lack of obvious catalysts may keep some investors away. Cinryze is expected to grow significantly, and this week, another analyst got behind the stock for just that reason.
- PropThink received considerable interest in Jason Napodano’s report on Spinal Cord Injury (SCI) and the publicly-listed companies that develop treatments: Stemcells (STEM), Neuralstem (CUR), and Invivo (NVIV).
- Keep an eye on SCLN, which has been recovering since lows near $4.25. Institutional interest is rising and fundamentals remain intact for the cheap stock.
- Shares of Telik spiked late last week, and PropThink noted the company’s poor balance sheet, suggesting that a capital raise is imminent and the pop wouldn’t last. The stock has fallen 40% since.
Additional disclosure: PropThink is a team of editors, analysts, and writers. Use of PropThink's research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at this link.